APA (7th ed.) Citation

Costa Svedman, F., Liapi, M., Chatzidionysiou, A., Månsson-Broberg, A., & Egyhazi Brage, S. (2023). 1152P Association of immune-related adverse events (irAE) requiring glucocorticoids (GCs) with outcome and biomarkers in advanced cutaneous malignant melanoma (CMM) treated with immune checkpoint inhibitors (ICI). Annals of Oncology, 34, S688. https://doi.org/10.1016/j.annonc.2023.09.2286

Chicago Style (17th ed.) Citation

Costa Svedman, F., M. Liapi, A. Chatzidionysiou, A. Månsson-Broberg, and S. Egyhazi Brage. "1152P Association of Immune-related Adverse Events (irAE) Requiring Glucocorticoids (GCs) with Outcome and Biomarkers in Advanced Cutaneous Malignant Melanoma (CMM) Treated with Immune Checkpoint Inhibitors (ICI)." Annals of Oncology 34 (2023): S688. https://doi.org/10.1016/j.annonc.2023.09.2286.

MLA (9th ed.) Citation

Costa Svedman, F., et al. "1152P Association of Immune-related Adverse Events (irAE) Requiring Glucocorticoids (GCs) with Outcome and Biomarkers in Advanced Cutaneous Malignant Melanoma (CMM) Treated with Immune Checkpoint Inhibitors (ICI)." Annals of Oncology, vol. 34, 2023, p. S688, https://doi.org/10.1016/j.annonc.2023.09.2286.